여자의사회 "남녀 양성평등 위해 정부와 공조"
순천향대서울병원, 이현옥홀 오픈 기념행사 성료
부산대병원, 지역 최초 의료·금융 융합 플랫폼
원자력병원, 7년째 암 진단 검사비 지원사업 실
고대 재생의학硏, 유케어트론과 협약 체결
서울아산병원, 병원 주출입구 열화상 카메라 설
의사 소득이 7급 공무원보다 적은 이유
韓 "우한폐렴 예방·치료, 한의학 적극 활용"
한국유나이티드제약, 지역사회 ‘따뜻한 명절나
충남대병원, 부패방지 시책평가 ‘1등급’
Pilot study: asymptomatic hyperuricemia patients with obesity and nonalcoholic fatty liver disease have increased risk of double contour sign
민홍기 교수(건국대병원 류마티스내과)
[ 2020년 01월 01일 20시 20분 ]
Asymptomatic hyperuricemia is a preliminary condition of gouty arthritis. Although a small percentage of asymptomatic hyperuricemia patients progress to symptomatic gouty arthritis , hyperuricemia is the most powerful predictor of gouty arthritis [2,3].
Gout is known to be associated with several chronic diseases [4-6]. Recently, asymptomatic hyperuricemia has been associated with hypertension, chronic kidney disease (CKD), diabetes mellitus, and metabolic syndrome [7-9]. Treatment guidelines for gout suggest using urate lowering therapy (ULT) when gout is confirmed and if accompanied by recurrent flare, tophi, renal stone,
or urate arthropathy . ULT is a beneficial therapy for gout and prevents recurrent flare ups and resolves tophi. However, indication of ULT in asymptomatic hyperuricemia has not been established. The Outcome Measures in Rheumatology (OMERACT) Ultrasound Gout Task Force group have proposed four definitions for ultrasonographic elementary lesions in gout, double contour sign (DCS), tophus, hyperechoic aggregates, and erosion , although conditions other than DCS had relatively low inter- and intra-reader reliability and the 2015 classification criteria for gout only included DCS on ultrasonographic findings [12,13]. DCS is a definite sign of crystal deposition in hyaline cartilage surface. Therefore, DCS could be assumed as a preliminary lesion of gouty arthritis. Although there are currently no treatment guidelines for asymptomatic hyperuricemia, identifying patients with asymptomatic hyperuricemia who have a preliminary lesion for gouty arthritis could help to select candidates for ULT. The present study was planned to compare the features of asymptomatic hyperuricemia patients with and without DCS. Additionally, we aimed to identify predictors of DCS in asymptomatic hyperuricemia patients.
Patient and public involvement We enrolled patients who came to the Armed Forces Capital Hospital due to incidentally identified hyperuricemia between January and April 2018. Hyperuricemia was defined as serum urate over 7 mg/dL . Inclusion criteria were as follows: (1) urate level over 7 mg/dL, (2) age over 18 years, (3) no previous history of arthritis. Patients who take a urate lowering agent or medication which could affect serum urate level such as diuretics, low dose salicylates, angiotensin II receptor blockers, and fenofibrate were excluded . Patients with heavy alcohol drinking were also excluded because alcohol consumption can affect serum urate level . All participants provided written informed consent prior to enrollment. All experiments were conducted in accordance with the Declaration of Helsinki (1964). This study was approved by the Institutional Review Board of the Armed Forces Capital Hospital (AFCH-18-IRB-009).
Ultrasonographic findings Skeletomuscular ultrasonography was performed by a trained rheumatologist, H.K.M. DCS was defined as an abnormal hyperechoic band over the superficial margin of the hyaline cartilage, independent of the angle of insonation . Ultrasonography was done at six articular joints, the tibiotalar, 1st metatarsophalangeal (MTP), and knee joint medial and lateral femoral condyles, bilaterally. DCS was checked as positive in each joint if at least one side of the joint showed DCS. Ultrasonography was performed in two dimensions by scanning across each joint, moving from medial to lateral and from distal to proximal. The medial and lateral condyles of the femur were assessed in a supine position with full knee flexion. To assess anterior recess of tibiotalar joint and MTP joint, patients were seated on the examination bed with the knee flexed 45º while placing the foot plantar surface flat . Two readers (H.K.M. and H.C.) decided the presence or absence of DCS independently. When two readers showed a discrepancy between their decisions, they rechecked the ultrasonography. If discordance existed after the re-estimation, an independent assessor (S.H.P.) made the final decision. Ultrasound was done using a multifrequency linear array transducer (8 to 13 MHz) of Logiq E (Philips Healthcare, Amsterdam, the Netherlands), on B mode.
Demographic, clinical, and laboratory profiles Patient demographic characteristics and laboratory data were collected at the time of first visit. Patient history included information about medication history, alcohol consumption, and smoking status. Comorbidities were investigated by history taking, and nonalcoholic fatty liver disease (NAFLD) was confirmed by liver ultrasonography and exclusion of alcoholic liver disease and viral steatohepatitis. Alcohol consumption was calculated in grams per day by asking the frequency and amount of alcohol consumed at each time. Patients with an alcohol consumption over 40 g/day were categorized as having alcoholic liver disease . Viral hepatitis markers for hepatitis B and C were checked to rule out steatohepatitis due to viral hepatitis. Dyslipidemia and hypertriglyceridemia were confirmed by checking the lipid profile according to the 2015 Korean Guideline for the management of dyslipidemia . Low density lipoprotein cholesterol over 160 mg/dL was classified as
dyslipidemia and triglycerides over 200 mg/dL as hypertriglyceridemia. Obesity was classified into three stages according to current guidelines from the Korean Society for the Study of Obesity: class I obesity, body mass index (BMI) 25 to 29.9; class II obesity, BMI 30 to 34.9; and class III obesity, BMI ≥ 35 .
Statistical analysis Continuous variables were compared by the Mann-Whitney test and displayed as median and interquartile range. Categorical variables were compared between groups using the chi-square test or Fisher’s exact test. Inter-reader reliability was estimated by unweighted Cohen’s κ statistic in terms of categorical assessment (presence or absence of DCS). Cohen’s κ values of 0 to 0.20 were considered as poor, 0.21 to 0.40 fair, 0.41 to 0.60 moderate, 0.61 to 0.80 good and > 0.80 excellent. Univariate and multivariate logistic regression analysis were performed, and factors that yielded a p < 0.05 by univariate analysis were considered for the multivariate analysis. Values of p < 0.05 were considered statistically significant. All tests were performed using R for Windows 3.3.2 (The R Foundation for Statistical Computing, Vienna, Austria).
Patient baseline characteristics and comparison between asymptomatic hyperuricemia patients with and without DCS A total of 62 patients with asymptomatic hyperuricemia were enrolled. All enrolled patients were male, and the median age was 38 years. Total 372 joints (six sites for each patient) was examined, and DCS was observed in 24 sites out of 22 of the enrolled patients, and MTP was the most common site (Table 1). Representative ultrasonographic images of DCS in each joint are shown in Fig. 1. Cohen’s κ value for existence of DCS was 0.78 (p = 0.016). Class II obesity and NAFLD were more frequent in asymptomatic hyperuricemia patients with DCS than in those without DCS (38.1% vs. 7.9%, p = 0.012; 50.0% vs. 12.81%, p = 0.004, respectively) (Table 1).
Factors associated with DCS in patients with asymptomatic hyperuricemia Univariate and multivariate logistic regression analysis
were conducted to identify factors associated with DCS. On univariate analysis, class II obesity (odds ratio [OR], 7.18; p = 0.009), NAFLD (OR, 6.80; p = 0.003), and smoking (OR, 3.52; p = 0.033) significantly increased the risk of DCS in patients with asymptomatic hyperuricemia. In multivariate analysis, class II obesity and NAFLD significantly increased the risk of DCS (Table 2).
Gout and asymptomatic hyperuricemia have been a recent focus because chronic diseases such as hypertension, CKD, and metabolic syndrome have been associated with gout and with asymptomatic hyperuricemia [4-9,21]. Previous discussion has raised the question that ULT might have beneficial effects not only on preventing gout flare, but also on related chronic diseases. One prospective study showed that ULT attenuated renal damage in asymptomatic hyperuricemia patients with CKD . However, evidence that supports the beneficial effects of ULT in asymptomatic hyperuricemia is insufficient, and internationally acceptable treatment guidelines have not yet been established. Dalbeth and Stamp  the stage of gout and asymptomatic hyperuricemia according to symptoms and ultrasonographic evidence of monosodium urate (MSU) deposit and proposed that early intervention for patients with asymptomatic hyperuricemia with MSU deposits could potentially have a preventive role. It is important to identify and select candidates among patients with asymptomatic hyperuricemia for ULT to prevent symptomatic gouty arthritis and related diseases. The present study showed that class II obesity and NAFLD were significantly associated with the presence of DCS in patients with asymptomatic hyperuricemia, and this finding might aid in selecting candidates with ULT. The OMERACT Ultrasound Gout Task Force group has suggested four elementary lesions in gout: tophi, hyperechoic aggregate, erosion, and DCS . However, recent classification criteria for gout have only included DCS as an ultrasonographic finding . Erosion proven by conventional radiography is also included in classification criteria, but it is a relatively common feature in inflammatory arthritis. Tophi are commonly seen in the synovium or tendon in cases of gout, but a recently published systemic review revealed that these findings had relatively low sensitivity for gouty arthritis . Several studies evaluated the presence of DCS in patients with asymptomatic hyperuricemia [14,24]. One study revealed that DCS was found in 25% and 17% of 1st MTP and femoral hyaline cartilage, respectively . The present
study showed similar results that 35.5% of patients with asymptomatic hyperuricemia had DCS, and that the MTP was the most frequently affected joint. Uric acid level is the most powerful predictor of development from asymptomatic hyperuricemia to gouty arthritis, but other factors, such as excessive weight gain also affect the occurrence of symptomatic gouty arthritis . The present study showed that class II obesity was significantly associated with presence of DCS. Adipose tissue secretes various adipokines, and adiponectin was negatively associated with urate level . However, the effect of adipokines on crystal deposits has not yet been elucidated. Further basic research could reveal whether adipokine and obesity have pathologic role on crystal deposit or not. Most patients with NAFLD are obese, but the present study showed a modest correlation between class II obesity and NAFLD (five NAFLD among 11 class II obesity patients, and five class II obesity cases among 16 NAFLD patients). To clarify and confirm the independent relationships between NAFLD, obesity, and crystal deposition, further studies on the mechanism between obesity, NAFLD, and crystal deposition should be investigated.
And it would be interesting research if follow-up data reveals the therapeutic effect of treating obesity and NAFLD on DCS. Interestingly, the most powerful predictor of gout flare, serum uric acid level, was not associated with DCS. However, in the present study, uric acid level was measured only once, and this is not representative of the average urate level. Duration of hyperuricemia state and mean level of serum uric acid may be more important on formation of crystal deposit, and it could be assessed by measuring urate levels over multiple time points. There were several limitations to this study. First, the present study was performed by cross-sectional analysis, therefore, the causality between obesity and NAFLD on DCS could not be proven. Second, the enrolled study population was relatively small. Third, the enrolled patients were all male and relatively young; therefore, the impact of obesity and NAFLD on female or elderly patients with asymptomatic hyperuricemia could not be evaluated. Forth, the joint fluid analysis was not performed in patients with DCS. Therefore, discriminating MSU from other crystal such as calcium pyrophosphate crystal was impossible in present study. Finally, the present study did not include other ultrasonographic findings for gout such as tophi and hyperechoic aggregates. Although DCS is the most representative finding in gout, there are several limitations with respect to confirming DCS. The detection rate for DCS depends on the sonographer’s proficiency, and inter-observer reliability is relatively variable. Despite the limitations, this was the first study which demonstrated risk factors for ultrasonographic proven crystal deposits in asymptomatic hyperuricemia patients. In conclusion, several differences were observed between asymptomatic hyperuricemia patients with and without DCS. Accompanying class II obesity and NAFLD were significantly associated with DCS in asymptomatic hyperuricemia patients. This association could be used to identify asymptomatic hyperuricemia patients who have preliminary lesions and that could benefit from ULT. Patients with asymptomatic hyperuricemia who have severe obesity and NAFLD could require ULT to prevent symptomatic gouty arthritis and to resolve crystal deposits.
(입금하실 입금자명 + 입금예정일자를 입력하세요)
- 관련뉴스가 없습니다.
이화여대 의무부총장 겸 의료원장 유경하·이대목동병원장 유재두·이대서울병원장 임수미
박양동 전(前) 경상남도의사회장 차남
송재준 제9대 대구가톨릭의료원장 취임
이형배 삼성서울병원 전무
우현구 교수(아주대 의대 생리학교실), 암 전문 국제학술지 카시노제네시스 편집위원
홍성빈 교수(인하대병원 내분비내과), 보건복지부 장관 표창
을지대병원 간호사회, 을지대 간호학과 학생 장학금 100만원
국립중앙의료원 공공보건의료인력 교육훈련심의위원, 감신·강철환·박훈기 교수 등 10명 위촉
식품의약품안전처 차장 양진영·의료기기안전국장 정용익 外
강릉시의사회, 대한의사협회 회관 신축기금 1000만원
정동균 유한양행 상무(마케팅부문장) 부친상
김영화 교수(대전성모병원 외과) 모친상
신창규 전(前) 대구의료원장 모친상
허갑범 허내과 원장(연세의대 명예교수, 김대중 前 대통령 주치의) 별세-한경진 아주의대 교수 장인상
우한폐렴 사태 주가 호재 진단업체
역대 최장수 재임 도전 박능후 보건복지부장관
임상시험 결과 발표 한올바이오파마 '도덕성' 논란
양심 불량 치과 전문의 교육 '대리출석'
환자 10명 중 9명 "간호사 서비스 만족"
간호대 후배 '인사법 등 군기잡기 관행' 폭로 시끌
심평원 고시 또 고시···짜증나는 원장들
(주)데일리메디의 모든 뉴스 및 컨텐츠는 저작권법 보호를 받으며, 무단복제 및 복사 배포를 금합니다
명칭 : (주)데일리메디 | 등록번호 : 서울 아00396 | 등록연월일 : 2007년7월10일 | 제호 : 데일리메디 | 발행인 : 안순범 | 편집인 : 박대진
발행소 : 04590 서울특별시 중구 다산로 162(신당동,약수빌딩) 5층 | 발행연월일 : 2002년 11월 5일 | TEL . 02-927-8955~7 | FAX .02-2231-9275 | 청소년보호책임자 : 박대진
정보제공사업 신고번호 : 서울청 제 2014-15호 | E-mail : firstname.lastname@example.org
보건의료문화를 선도하는 데일리메디
All rights reserved.